MarthaWadleighMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Wadleigh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wadleigh's full profile

Already have an account?

Office
44 Binney St
# 1B25
Boston, MA 02115
Phone+1 617-632-6685

Fax+1 617-582-8202

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
Duke University HospitalResidency, Internal Medicine, 1998 - 2001
Duke University School of MedicineClass of 1998

Certifications & Licensure

MA State Medical License 2004 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Clinical Trials

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 2005 Sep 01
Completed
Phase 1
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia Start of enrollment: 2008 Jun 01
Unknown status
Phase 1, Phase 2
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Start of enrollment: 2009 Nov 01
Completed
Phase 1, Phase 2
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia Start of enrollment: 2014 Feb 07
Completed
Phase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Aug 10
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

10 citations
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.
Shai Shimony, Yael Flamand, Yannis K Valtis, Andrew E Place, Lewis B Silverman
Blood Advances. 2023-09-26
33 citations
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Elizabeth A Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird
Journal of the National Comprehensive Cancer Network. 2022-05-01
258 citations
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatm...
Ayalew Tefferi, Giovanni Barosi, Ruben A. Mesa, Francisco Cervantes, H. Joachim Deeg
Blood. 2006-09-01

Abstracts/Posters

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
Martha Wadleigh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all